Literature DB >> 10811332

Persistence of abnormal gastrointestinal motility after operation for Hirschsprung's disease.

E Miele1, A Tozzi, A Staiano, C Toraldo, C Esposito, R E Clouse.   

Abstract

OBJECTIVE: Recent studies in patients with Hirschsprung's disease (HD) suggest that morphological abnormalities of the intramural intestinal plexuses are not restricted to the colon. In this report, symptoms and objective tests of gastrointestinal (GI) motor dysfunction were determined long after operative treatment to see whether evidence of a more widespread and relevant motility disturbance could be detected.
METHODS: Twenty-one children were available for study an average of 6.6 yr after surgery for HD. All of these patients underwent evaluation of bowel frequency per week, total GI transit time (TGTT), and a scintigraphic gastric emptying test using solid food; anorectal manometry and segmental colonic transit times were performed in a subset of patients. Results were compared with findings in appropriately matched controls.
RESULTS: Frequency of defecation per week in patients with HD after surgery was not different from that in control children, but TGTT was significantly longer (p < 0.01). Percentage retention of gastric isotope at 60 min exceeded the normal range in 12 of 21 (57.1%) patients, and colonic transit was abnormal in all six children studied. Symptoms persisted in two-thirds of patients postoperatively, and transit abnormalities were more common in the symptomatic subset (p = 0.026).
CONCLUSIONS: Our data show that, in a subset of patients with HD, GI motor dysfunction persists long after surgical correction. The heterogeny of basic defects responsible for HD could provide the substrate for these motor abnormalities that, in turn, seem at least partially responsible for continuation of the symptomatic state.

Entities:  

Mesh:

Year:  2000        PMID: 10811332     DOI: 10.1111/j.1572-0241.2000.02014.x

Source DB:  PubMed          Journal:  Am J Gastroenterol        ISSN: 0002-9270            Impact factor:   10.864


  8 in total

1.  Hirschsprung's Disease.

Authors:  William M. Belknap
Journal:  Curr Treat Options Gastroenterol       Date:  2003-06

2.  Genetic background impacts developmental potential of enteric neural crest-derived progenitors in the Sox10Dom model of Hirschsprung disease.

Authors:  Lauren C Walters; V Ashley Cantrell; Kevin P Weller; Jack T Mosher; E Michelle Southard-Smith
Journal:  Hum Mol Genet       Date:  2010-08-25       Impact factor: 6.150

3.  Assessment of colonic transit time using MRI: a feasibility study.

Authors:  Sonja Buhmann; Chlodwig Kirchhoff; Roland Ladurner; Thomas Mussack; Maximilian F Reiser; Andreas Lienemann
Journal:  Eur Radiol       Date:  2006-10-12       Impact factor: 5.315

Review 4.  Gastroparesis in children.

Authors:  Efstratios Saliakellis; Maria Fotoulaki
Journal:  Ann Gastroenterol       Date:  2013

5.  Interest of Anorectal Manometry During Long-term Follow-up of Patients Operated on for Hirschsprung's Disease.

Authors:  Viet Q Tran; Tania Mahler; Patrick Bontems; Dinh Q Truong; Annie Robert; Philippe Goyens; Henri Steyaert
Journal:  J Neurogastroenterol Motil       Date:  2018-01-30       Impact factor: 4.924

6.  Ednrb -/- mice with hirschsprung disease are missing Gad2-expressing enteric neurons in the ganglionated small intestine.

Authors:  Sukhada Bhave; Richard A Guyer; Nicole Picard; Meredith Omer; Ryo Hotta; Allan M Goldstein
Journal:  Front Cell Dev Biol       Date:  2022-07-26

7.  Pan-enteric neuropathy and dysmotility are present in a mouse model of short-segment Hirschsprung disease and may contribute to post-pullthrough morbidity.

Authors:  Sukhada Bhave; Emily Arciero; Corey Baker; Wing Lam Ho; Richard A Guyer; Ryo Hotta; Allan M Goldstein
Journal:  J Pediatr Surg       Date:  2020-04-17       Impact factor: 2.545

8.  Up-regulated FHL1 expression maybe involved in the prognosis of Hirschsprung's disease.

Authors:  Li-Li Wang; Hui Gu; Yang Fan; Yi Zhang; Di Wu; Jia-Ning Miao; Tian-Chu Huang; Hui Li; Zheng-Wei Yuan
Journal:  Int J Med Sci       Date:  2014-01-20       Impact factor: 3.738

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.